Dr. Christina Smolke heads a world-leading research program in the areas of synthetic biology, yeast metabolic engineering, and biomolecular engineering. She has Valium pioneered the development of yeast biosynthesis platforms for an important class of plant natural products – the benzylisoquinoline alkaloids. Her innovative vision and research have been recognized with numerous awards, including the NIH Director’s Pioneer Award, WTN Award in Biotechnology, and TR35 Award. Dr. Smolke is an Associate Professor, Associate Chair of Education, and W.M. Keck Foundation Faculty Scholar in the Bioengineering Department at Stanford University. Dr. Smolke is currently on leave from her position at Stanford University to Tramadol lead the startup company, Antheia.